In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine

Li Heng Pao, Cheng Huei Hsiong, Oliver Yoa Pu Hu, Jhi Jung Wang, Shung Tai Ho

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A diester prodrug of nalbuphine, sebacoyl dinalbuphine (SDN), and its long-acting formulation are currently being developed to prolong the duration of nalbuphine. A comparative in vitro hydrolysis study was conducted for SDN in rat, rabbit, dog, and human blood. Both SDN and nalbuphine in blood or plasma were measured by high-performance liquid chromatography. The hydrolysis rates of SDN in blood were ranked as follows: rat > rabbit > human > dog. The rapid formation of nalbuphine in the blood accounted for almost 100% of the prodrug, which supported the contention that nalbuphine is the major metabolite after SDN hydrolysis. The hydrolysis profiles of SDN were similar both in plasma and in red blood cells when compared in the blood. In vitro release results of SDN long-acting formulation showed that the rate-limited step of SDN hydrolysis to nalbuphine in blood is the penetration of SDN from oil into the blood. After intravenous administration of SDN in sesame oil into rats, nalbuphine quickly appeared in plasma and, thereafter, exhibited monoexponential decay. Pharmaceutical dosage forms affecting the drug disposition kinetics were demonstrated after intravenous administration. The AUC of nalbuphine was significantly higher and clearance was significantly lower, without changes in the t1/2 of nalbuphine after intravenous dosing of SDN in sesame oil when compared with that of intravenous dosing with nalbuphine HCl in rats. Overall, these results suggest that SDN fulfilled the original pro-soft drug design in which the prodrug can rapidly metabolize to nalbuphine, and no other unexpected compounds were apparent in the blood.

Original languageEnglish
Pages (from-to)395-402
Number of pages8
JournalDrug Metabolism and Disposition
Volume33
Issue number3
DOIs
Publication statusPublished - Mar 1 2005
Externally publishedYes

Fingerprint

Nalbuphine
Pharmacokinetics
Prodrugs
Hydrolysis
Sesame Oil
Intravenous Administration
In Vitro Techniques
Dogs
Rabbits
Drug Design
Dosage Forms
Area Under Curve

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine. / Pao, Li Heng; Hsiong, Cheng Huei; Hu, Oliver Yoa Pu; Wang, Jhi Jung; Ho, Shung Tai.

In: Drug Metabolism and Disposition, Vol. 33, No. 3, 01.03.2005, p. 395-402.

Research output: Contribution to journalArticle

Pao, Li Heng ; Hsiong, Cheng Huei ; Hu, Oliver Yoa Pu ; Wang, Jhi Jung ; Ho, Shung Tai. / In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine. In: Drug Metabolism and Disposition. 2005 ; Vol. 33, No. 3. pp. 395-402.
@article{badef7ebe50d49209d4b13ffca821bf1,
title = "In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine",
abstract = "A diester prodrug of nalbuphine, sebacoyl dinalbuphine (SDN), and its long-acting formulation are currently being developed to prolong the duration of nalbuphine. A comparative in vitro hydrolysis study was conducted for SDN in rat, rabbit, dog, and human blood. Both SDN and nalbuphine in blood or plasma were measured by high-performance liquid chromatography. The hydrolysis rates of SDN in blood were ranked as follows: rat > rabbit > human > dog. The rapid formation of nalbuphine in the blood accounted for almost 100{\%} of the prodrug, which supported the contention that nalbuphine is the major metabolite after SDN hydrolysis. The hydrolysis profiles of SDN were similar both in plasma and in red blood cells when compared in the blood. In vitro release results of SDN long-acting formulation showed that the rate-limited step of SDN hydrolysis to nalbuphine in blood is the penetration of SDN from oil into the blood. After intravenous administration of SDN in sesame oil into rats, nalbuphine quickly appeared in plasma and, thereafter, exhibited monoexponential decay. Pharmaceutical dosage forms affecting the drug disposition kinetics were demonstrated after intravenous administration. The AUC of nalbuphine was significantly higher and clearance was significantly lower, without changes in the t1/2 of nalbuphine after intravenous dosing of SDN in sesame oil when compared with that of intravenous dosing with nalbuphine HCl in rats. Overall, these results suggest that SDN fulfilled the original pro-soft drug design in which the prodrug can rapidly metabolize to nalbuphine, and no other unexpected compounds were apparent in the blood.",
author = "Pao, {Li Heng} and Hsiong, {Cheng Huei} and Hu, {Oliver Yoa Pu} and Wang, {Jhi Jung} and Ho, {Shung Tai}",
year = "2005",
month = "3",
day = "1",
doi = "10.1124/dmd.104.002451",
language = "English",
volume = "33",
pages = "395--402",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - In vitro and in vivo evaluation of the metabolism and pharmacokinetics of sebacoyl dinalbuphine

AU - Pao, Li Heng

AU - Hsiong, Cheng Huei

AU - Hu, Oliver Yoa Pu

AU - Wang, Jhi Jung

AU - Ho, Shung Tai

PY - 2005/3/1

Y1 - 2005/3/1

N2 - A diester prodrug of nalbuphine, sebacoyl dinalbuphine (SDN), and its long-acting formulation are currently being developed to prolong the duration of nalbuphine. A comparative in vitro hydrolysis study was conducted for SDN in rat, rabbit, dog, and human blood. Both SDN and nalbuphine in blood or plasma were measured by high-performance liquid chromatography. The hydrolysis rates of SDN in blood were ranked as follows: rat > rabbit > human > dog. The rapid formation of nalbuphine in the blood accounted for almost 100% of the prodrug, which supported the contention that nalbuphine is the major metabolite after SDN hydrolysis. The hydrolysis profiles of SDN were similar both in plasma and in red blood cells when compared in the blood. In vitro release results of SDN long-acting formulation showed that the rate-limited step of SDN hydrolysis to nalbuphine in blood is the penetration of SDN from oil into the blood. After intravenous administration of SDN in sesame oil into rats, nalbuphine quickly appeared in plasma and, thereafter, exhibited monoexponential decay. Pharmaceutical dosage forms affecting the drug disposition kinetics were demonstrated after intravenous administration. The AUC of nalbuphine was significantly higher and clearance was significantly lower, without changes in the t1/2 of nalbuphine after intravenous dosing of SDN in sesame oil when compared with that of intravenous dosing with nalbuphine HCl in rats. Overall, these results suggest that SDN fulfilled the original pro-soft drug design in which the prodrug can rapidly metabolize to nalbuphine, and no other unexpected compounds were apparent in the blood.

AB - A diester prodrug of nalbuphine, sebacoyl dinalbuphine (SDN), and its long-acting formulation are currently being developed to prolong the duration of nalbuphine. A comparative in vitro hydrolysis study was conducted for SDN in rat, rabbit, dog, and human blood. Both SDN and nalbuphine in blood or plasma were measured by high-performance liquid chromatography. The hydrolysis rates of SDN in blood were ranked as follows: rat > rabbit > human > dog. The rapid formation of nalbuphine in the blood accounted for almost 100% of the prodrug, which supported the contention that nalbuphine is the major metabolite after SDN hydrolysis. The hydrolysis profiles of SDN were similar both in plasma and in red blood cells when compared in the blood. In vitro release results of SDN long-acting formulation showed that the rate-limited step of SDN hydrolysis to nalbuphine in blood is the penetration of SDN from oil into the blood. After intravenous administration of SDN in sesame oil into rats, nalbuphine quickly appeared in plasma and, thereafter, exhibited monoexponential decay. Pharmaceutical dosage forms affecting the drug disposition kinetics were demonstrated after intravenous administration. The AUC of nalbuphine was significantly higher and clearance was significantly lower, without changes in the t1/2 of nalbuphine after intravenous dosing of SDN in sesame oil when compared with that of intravenous dosing with nalbuphine HCl in rats. Overall, these results suggest that SDN fulfilled the original pro-soft drug design in which the prodrug can rapidly metabolize to nalbuphine, and no other unexpected compounds were apparent in the blood.

UR - http://www.scopus.com/inward/record.url?scp=14044259322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14044259322&partnerID=8YFLogxK

U2 - 10.1124/dmd.104.002451

DO - 10.1124/dmd.104.002451

M3 - Article

C2 - 15608131

AN - SCOPUS:14044259322

VL - 33

SP - 395

EP - 402

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 3

ER -